Last reviewed · How we verify
NCT07171294
Reproducibility of Minimally Invasive Surgery for Grade III Hemorrhoids
trial testing Minimal invasive hemorrhoidectomy in Hemorrhoidectomy in 20 participants. Participants enrolled and being followed up; not accepting new ones.
31 January 2026
Quick facts
| Lead sponsor | Hospital Son Llatzer |
|---|---|
| Status | Active, enrolled |
| Study type | OBSERVATIONAL |
| Enrollment | 20 |
| Start date | 12 August 2025 |
| Primary completion | 31 January 2026 |
| Estimated completion | 31 January 2026 |
| Sites | 1 location across Spain |
Drugs / interventions tested
- Minimal invasive hemorrhoidectomy
Conditions studied
- Hemorrhoidectomy — all drugs for Hemorrhoidectomy →
- Minimal Invasive Surgery — all drugs for Minimal Invasive Surgery →
Sponsor
Hospital Son Llatzer
Who can join
18 and older, any sex, with Hemorrhoidectomy or Minimal Invasive Surgery. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Hemorrhoids are vascular-elastic structures of the anal canal that contribute to continence. Their enlargement and descent lead to symptoms such as rectal bleeding and the sensation of anal swelling, known as hemorrhoidal syndrome. In advanced cases (Goligher Grade III-IV), surgery is the only effective treatment. Open excisional hemorrhoidectomy (OEH), based on the Milligan-Morgan technique, is the standard procedure. Although effective in the long term, it causes severe postoperative pain. Minimally invasive surgery (MIS) employs enhanced visualization devices to improve surgical precision and reduce tissue damage. While widely used in specialties with small surgical fields, it has not yet been explored in anal surgery. Its advantages include reduced tissue injury and improved healing, although it presents a learning curve and an initially longer surgical time. The IDEAL framework evaluates surgical innovations in five stages: Idea, Development, Exploration, Evaluation, and Long-Term Study. The IDEAL phase 2a is aimed at the optimization and technical definition of surgical innovation with a focus on continuous improvement based on real clinical practice, laying the foundation for broader and more rigorous subsequent studies. Since no previous studies on the application of MIS in OEH have been found, the investigators propose a study within Stage 2A of the IDEAL model to assess the reproducibility of this technique. The investigators believe its incorporation into open excisional hemorrhoidectomy could result in less postoperative pain and faster patient recovery.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07171294
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Minimal invasive hemorrhoidectomy
Trials testing the same drug.
- NCT06851312 — Implementation of Minimally Invasive Surgery for Grade III Hemorrhoids · completed
Other recruiting trials for Hemorrhoidectomy
Currently open trials in the same condition.
- NCT06747195 — The Impact of Methylene Blue on the Quality of Recovery in Patients Undergoing Hemorrhoidectomy · recruiting
Other Hospital Son Llatzer trials
Trials by the same sponsor.
- NCT07534761 — MINIMALLY INVASIVE SURGERY FOR GRADE III HEMORRHOIDS · not yet recruiting
- NCT06764849 — Minimally Invasive Open Excisional Hemorrhoidectomy Compared to Conventional Open Excisional Hemorrhoidectomy: a Clinica · NA · withdrawn
- NCT06851312 — Implementation of Minimally Invasive Surgery for Grade III Hemorrhoids · completed
- NCT06420986 — Open Hemorrohoidectomy Vs Transanal Hemorrhoidal Desarterialization in Hemorrhoids Grade III: The Effect on Symptoms · NA · completed
- NCT06484660 — Efficacy Of Minimally Invasive Approach In The Surgical Treatment Of Complex Perianal Fistula · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07171294 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hospital Son Llatzer
- Last refreshed: 3 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07171294.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing